Reaction

Upper Respiratory Tract Congestion reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,882 reports · 54 co-occurring drugs

As of the last recalculation, Upper Respiratory Tract Congestion appears in 2,882 FAERS reports alongside 54 co-occurring drug terms. The strongest observed disproportionality signal is CICLESONIDE (PRR 20.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ciclesonide	38	20.4	20.5
Nirmatrelvir And Ritonavir	135	18.8	18.9
Epoprostenol	19	10.5	10.6
Ambrisentan	138	8.3	8.3
Umeclidinium Bromide And Vilanterol Trifenatate	17	7.4	7.4
Nitrofurantoin	16	7.0	7.0
Nitrofurantoin (Monohydrate/Macrocrystals)	16	6.9	7.0
Omalizumab	80	6.9	6.9
Fluticasone Furoate And Vilanterol Trifenatate	31	6.3	6.3
Budesonide And Formoterol Fumarate Dihydrate	82	6.3	6.3
Vilazodone Hydrochloride	7	5.5	5.5
Fluticasone Propionate And Salmeterol	31	5.4	5.4
Palivizumab	11	5.2	5.2
Montelukast Sodium	85	5.2	5.2
Infliximab-Dyyb	20	5.0	5.0
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	14	4.9	4.9
Naproxen Sodium, Pseudoephedrine Hydrochloride	14	4.9	4.9
Naproxen Sodium Tablet, Coated	9	4.8	4.8
Naproxen Sodium, Coated Tablets	9	4.8	4.8
Naproxen Sodium 220Mg	9	4.8	4.8
Mepolizumab	32	4.7	4.7
Fluticasone Propionate And Salmeterol Xinafoate	38	4.6	4.6
Ocrelizumab	39	4.6	4.6
Desoximetasone	12	4.6	4.6
Tadalafil	62	4.5	4.6
Pirfenidone	25	4.5	4.5
Ofatumumab	20	4.4	4.4
Etanercept	322	4.2	4.2
Riociguat	19	4.2	4.2
Selexipag	15	4.2	4.2
Natalizumab	103	4.2	4.2
Macitentan	38	4.0	4.0
Agalsidase Beta	5	3.9	3.9
Tiotropium Bromide	68	3.6	3.6
Loratadine And Pseudoephedrine Sulfate	4	3.6	3.6
Vibegron	4	3.6	3.6
Tofacitinib	83	3.3	3.3
Belimumab	13	3.0	3.0
Niraparib	9	2.9	2.9
Alirocumab	9	2.6	2.6
Rucaparib	3	2.5	2.5
Sodium Oxybate	22	2.4	2.4
Treprostinil	41	2.4	2.4
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	13	2.3	2.3
Axitinib	6	2.2	2.2
Palbociclib	29	2.2	2.2
Peginterferon Beta-1A	4	2.2	2.2
Dimethyl Fumarate	33	1.9	1.9
Exenatide	14	1.9	1.9
Bimekizumab	5	1.7	1.7
Apremilast	33	1.6	1.6
Docosanol	3	1.5	1.5
Dupilumab	90	1.4	1.4
Evolocumab	22	1.0	1.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.